Reynolds et al., Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19. N Engl J Med 2020; 382:2441-2448. DOI: 10.1056/NEJMoa2008975
https://www.nejm.org/doi/full/10.1056/NEJMoa2008975

University of California, Berkeley

- Inhibitors of the Renin–Angiotensin–Aldosterone System and Covid-19 (Editorial)
- Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19 (article)
- Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19 (article)
- Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19 (article)

The New England Journal of Medicine Papers Related to COVID-19 Patient Comorbidities

John A. Jarcho, M.D., Julie R. Ingelfinger, M.D., Mary Beth Hamel, M.D., M.P.H., Ralph B. D’Agostino, Sr., Ph.D., and David P. Harrington, Ph.D. Inhibitors of the Renin–Angiotensin–Aldosterone System and Covid-19. The New England Journal of Medicine (June 2020). DOI: 10.1056/NEJMe2012924
https://www.nejm.org/doi/full/10.1056/NEJMe2012924?query=recirc_curatedRelated_article

Inhibitors of the Renin–Angiotensin–Aldosterone System and Covid-19

Mandeep R. Mehra, M.D., Sapan S. Desai, M.D., Ph.D., SreyRam Kuy, M.D., M.H.S., Timothy D. Henry, M.D., and Amit N. Patel, M.D. Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. N Engl J Med 2020; 382:e102 (June 2020) DOI: 10.1056/NEJMoa2007621
https://www.nejm.org/doi/full/10.1056/NEJMoa2007621

Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19


Giuseppe Mancia, M.D., Federico Rea, Ph.D., Monica Ludergnani, M.Sc., Giovanni Apolone, M.D., and Giovanni Corrao, Ph.D. Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19. N Engl J Med 2020; 382:2431-2440. DOI: 10.1056/NEJMoa2006923
https://www.nejm.org/doi/full/10.1056/NEJMoa2006923

Learn Before

Related